Car-T cell therapy for relapsed or refractory leukemia and lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests whether a new immune therapy (CAR-T cells) can treat certain types of blood cancers that have come back or not responded to standard treatments. It aims to help people with aggressive B-cell lymphoma or acute lymphoblastic leukemia (ALL) that hasn't been controlled by other therapies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of B-cell lymphoma (like DLBCL) or B-cell acute lymphoblastic leukemia that has relapsed or not responded to at least two prior treatments.
- Your cancer must be measurable, meaning it shows up on scans or in bone marrow tests.
- You should be between 18 and 70 years old for lymphoma, or between 3 and 24 years old for leukemia.
- Your overall health must be good enough for the therapy, with adequate kidney, liver, and blood cell counts.
- You must agree to use effective birth control for one year after treatment if you could become pregnant or father a child.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a type of immunotherapy called CAR-T cells that are made from your own blood cells and are designed to find and destroy leukemia cells. It is for patients whose leukemia has come back or hasn't gone away after other treatments.
This trial tests a new CAR-T cell therapy for children, teens, and young adults with acute lymphoblastic leukemia that has not responded to standard treatment. The goal is to see if the therapy can put the leukemia into remission so the patient may then have a stem cell transplant.
This trial tests a new immunotherapy using your own immune cells (CAR T-cells) that are modified to find and kill cancer cells that have a protein called CD19 or CD22. It is for adults whose acute lymphoblastic leukemia (ALL) or lymphoma has come back or did not respond to previous treatments.
This trial tests a new CAR-T cell therapy (a type of immune cell treatment) for patients with a specific kind of B-cell lymphoma that has come back or not responded to previous therapy. The treatment targets a protein called CD19 on the cancer cells to help your immune system fight the lymphoma.
This trial tests a new type of cell therapy (CAR T) that targets two markers on lymphoma cells, CD19 and CD22. It is for people with aggressive B-cell lymphoma that has not responded to standard treatments.
This trial tests a new CAR-T cell therapy (called ssCART-19) for people with B-cell lymphoma that has not responded to standard treatments or has come back. The therapy uses your own immune cells to target and kill cancer cells.
Hear when a new Leukemia, Acute Lymphoblastic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.